I am wondering if anyone has a good and easy way of comparing RNA-Seq data and qPCR result/validation statistically. I have seen papers comparing the microarray data and qPCR but not RNA-Seq data. Any help would be highly appreciate.
Unconfigured Ad
Collapse
X
-
There are papers with comparison of RNA-seq and qPCR data. Check out for instance Griffith et al, Nature Methods 2010, or Asmann et al BMC Genomics, 2009. Probably the Mortazavi et al too, and those from the Burge lab.Originally posted by upendra_35 View PostI am wondering if anyone has a good and easy way of comparing RNA-Seq data and qPCR result/validation statistically. I have seen papers comparing the microarray data and qPCR but not RNA-Seq data. Any help would be highly appreciate.
-
-
For added convenience to people landing here ... in Griffith et al. Nature Methods. 2010 Oct;7(10):843-847 [Abstract | Full Text | PDF | Supplementary Materials] the qPCR validations are presented in Figure 2. The experiment involved qPCR validation of 192 differentially expressed exons identified in the RNA-seq data. An additional qualitative assay involving RT-PCR, gel electrophoresis and Sanger sequencing was used to validate 189 exon-skipping junctions (see Supplementary Figure 10a in the Supplementary Materials). The actual data values are available from the ALEXA-seq website here. The validation rates for the quantitative and qualitative assays were 88% and 85% respectively. The selection of targets for validation was not biased towards highly expressed exons. Actually it was biased towards lowly expressed exons that were nevertheless identified as expressed above background by RNA-seq. These likely represent minor isoforms in many cases (see Supplementary Figure 10b in the Supplementary Materials). The paper also includes direct comparison to both Affymetrix exon arrays and custom NimbleGen splicing microarrays.
Comment
-
-
Hi!
In lack of more cDNA I only have 12 genes from qPCR.. I want to compare edgeR vs DESeq2 vs Cuffdiff and see which I will use based on match with qPCR:
YES/no indicates if it is significantly changed.
Gene qPCR edgeR DESeq2 Cuffdiff
1 no YES no no
2 YES YES no no
3 no no no no
4 YES YES no no
5 YES no no no
6 no no no no
7 no no no no
8 no no no no
9 no no no no
10 no no no no
11 no no no no
12 no no no no
I really want to use edgeR, but is this test good enought?
Comment
-
-
I'm not sure why you tested 8 of those since they weren't DE according to any of the programs (I assume #5 was either borderline or had a huge foldchange). Given your effective n=3 of informative genes, edgeR would seem to be in the lead. However, you haven't tested any that DESeq2 or cuffdiff uniquely called DE. BTW, making more cDNA doesn't even take an hour...
Comment
-
Latest Articles
Collapse
-
by SEQadmin2
Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.
The systematic characterization of the human proteome has...-
Channel: Articles
07-20-2026, 11:48 AM -
-
by SEQadmin2
Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
...-
Channel: Articles
07-09-2026, 11:10 AM -
-
by SEQadmin2
Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.
There is no single reason why many patients don’t respond to treatment as expected. Cancer is...-
Channel: Articles
07-08-2026, 05:17 AM -
ad_right_rmr
Collapse
News
Collapse
| Topics | Statistics | Last Post | ||
|---|---|---|---|---|
|
Started by SEQadmin2, Today, 12:17 PM
|
0 responses
10 views
0 reactions
|
Last Post
by SEQadmin2
Today, 12:17 PM
|
||
|
Started by SEQadmin2, Yesterday, 11:41 AM
|
0 responses
11 views
0 reactions
|
Last Post
by SEQadmin2
Yesterday, 11:41 AM
|
||
|
Started by SEQadmin2, 07-20-2026, 11:10 AM
|
0 responses
23 views
0 reactions
|
Last Post
by SEQadmin2
07-20-2026, 11:10 AM
|
||
|
Started by SEQadmin2, 07-13-2026, 10:26 AM
|
0 responses
37 views
0 reactions
|
Last Post
by SEQadmin2
07-13-2026, 10:26 AM
|
Comment